Epigenetic activation of antiviral sensors and effectors of interferon response pathways during SARS-CoV-2 infection
Bińkowski, Jan (Institució Catalana de Recerca i Estudis Avançats)
Taryma-Leśniak, Olga (Institució Catalana de Recerca i Estudis Avançats)
Łuczkowska, Karolina (Pomeranian Medical University in Szczecin, Poland)
Niedzwiedź, Anna (Independent Public Regional Hospital in Szczecin, Poland)
Lechowicz, Kacper (Pomeranian Medical University in Szczecin, Poland)
Strapagiel, Dominik (University of Lodz, Poland)
Jarczak, Justyna (University of Lodz, Poland)
Davalos, Veronica (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Pujol, Aurora 1968- (Institut d'Investigació Biomèdica de Bellvitge)
Esteller, M (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Kotfis, Katarzyna (Pomeranian Medical University in Szczecin, Poland)
Machaliński, Boguslaw (Pomeranian Medical University in Szczecin, Poland)
Parczewski, Milosz (Pomeranian Medical University in Szczecin, Poland)
Wojdacz, Tomasz K. (Aarhus University, Denmark)

Date:	2022
Abstract:	Recent studies have shown that methylation changes identified in blood cells of COVID-19 patients have a potential to be used as biomarkers of SARS-CoV-2 infection outcomes. However, different studies have reported different subsets of epigenetic lesions that stratify patients according to the severity of infection symptoms, and more importantly, the significance of those epigenetic changes in the pathology of the infection is still not clear. We used methylomics and transcriptomics data from the largest so far cohort of COVID-19 patients from four geographically distant populations, to identify casual interactions of blood cells' methylome in pathology of the COVID-19 disease. We identified a subset of methylation changes that is uniformly present in all COVID-19 patients regardless of symptoms. Those changes are not present in patients suffering from upper respiratory tract infections with symptoms similar to COVID-19. Most importantly, the identified epigenetic changes affect the expression of genes involved in interferon response pathways and the expression of those genes differs between patients admitted to intensive care units and only hospitalized. In conclusion, the DNA methylation changes involved in pathophysiology of SARS-CoV-2 infection, which are specific to COVID-19 patients, can not only be utilized as biomarkers in the disease management but also present a potential treatment target.
Note:	Altres ajuts: Polish National Agency for Academic Exchange grant number: PPN/PPO/2018/1/00088/U; European Regional Development Fund of the West Pomeranian Province 2014-2020, PROTO_LAB/K1/2020/U/18
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	COVID-19 ; Coronavirus ; SARS-CoV-2 ; Epigenetics ; DNA methylation
Published in:	Biomedicine & pharmacotherapy, Vol. 153 (september 2022) , ISSN 1950-6007

DOI: 10.1016/j.biopha.2022.113396
PMID: 36076479

14 p, 8.9 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP) > Josep Carreras Leukaemia Research Institute
Articles > Research articles
Articles > Published articles